2024
Feasibility of a prospective pediatric melanocytic tumor clinical trial: A report of multidisciplinary clinician survey data from the Children's Oncology Group Rare Tumor Committee
Mitchell S, Christison‐Lagay E, Aldrink J, Sargen M, Laetsch T, Austin M, Jen M, Gartrell R, Karunamurthy A, Kirkwood J, Pappo A, Seynnaeve B. Feasibility of a prospective pediatric melanocytic tumor clinical trial: A report of multidisciplinary clinician survey data from the Children's Oncology Group Rare Tumor Committee. Pediatric Blood & Cancer 2024, 71: e31312. PMID: 39252525, DOI: 10.1002/pbc.31312.Peer-Reviewed Original Research
2023
Implications of Immunotherapy for Pediatric Malignancies: A Summary from the APSA Cancer Committee
Talbot L, Lautz T, Aldrink J, Ehrlich P, Dasgupta R, Mattei P, Tracy E, Glick R, Grant C, Brown E, Christison-Lagay E, Rodeberg D. Implications of Immunotherapy for Pediatric Malignancies: A Summary from the APSA Cancer Committee. Journal Of Pediatric Surgery 2023, 58: 2119-2127. PMID: 37550134, DOI: 10.1016/j.jpedsurg.2023.07.001.Peer-Reviewed Original ResearchAPSA Cancer CommitteeClass of immunotherapyT-cell therapyCancer CommitteePediatric malignanciesChimeric antigen receptor T-cell therapyMonoclonal antibody checkpoint inhibitorsTransgenic T cell receptorBispecific T-cell engagersCell therapyEarly phase clinical trialsYoung adultsConventional chemotherapeutic regimensDisease-related deathT-cell engagersClass of therapyT cell receptorCare of childrenCheckpoint inhibitorsAdverse eventsMetastatic diseaseSystemic treatmentChemotherapeutic regimensSurgical interventionClinical trials